Galectin Therapeutics, led by CEO Joel Lewis, participated in a conference on September 2, 2025, discussing their work on developing therapies for MASH with cirrhosis.
5 reports, 3 independent
Updated Oct 6
Gone quiet
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Galectin Therapeutics, led by CEO Joel Lewis, participated in a conference on September 2, 2025, discussing their work on developing therapies for MASH with cirrhosis.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Galectin Therapeutics submitted Phase 3 protocol for belapectin review to the FDA.1 source
FDA agrees on Phase 3 trial elements for belapectin; Joel Lewis remains CEO.1 source
Galectin Therapeutics discussed MASH therapies with cirrhosis at a conference on September 2, 2025.1 source
Keep exploring
The entities involved
-
mash
fast genome and metagenome distance estimation using MinHash
Coverage
Newest first; wire copies grouped- manilatimes.net
- finanznachrichten.de
- GlobeNewswireGalectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the lead
- Unknown outlet